Products DT5aP-IPV-Hib 5-component Pertussis vaccine + Infanrix® -IPV+Hib
DT5aP-IPV-Hib 5-component Pertussis vaccine + Infanrix® -IPV+Hib Phase 3 Completed 📈 Rising Pertussis, Diphtheria, Tetanus, Poliomyelitis, Haemophilus Influenzae Type b
Feb 1, 2006 → Sep 1, 2008
About DT5aP-IPV-Hib 5-component Pertussis vaccine + Infanrix® -IPV+Hib DT5aP-IPV-Hib 5-component Pertussis vaccine + Infanrix® -IPV+Hib is a phase 3 stage product being developed by Sanofi for Pertussis. The current trial status is completed. This product is registered under clinical trial identifier NCT00287092. Target conditions include Pertussis, Diphtheria, Tetanus.
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT00287092 Phase 3 Completed Feb 1, 2006 Sep 1, 2008 Pertussis
Product Company Stage Hype Score Adacel® Sanofi Approved aP booster + TdaP booster + Licensed TdaP booster (Boostrix®) Novartis Phase 1 Boostrix + Placebo (Saline) Novartis Approved Acellular pertussis vaccine + Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) + Licensed TdaP booster vaccine + Diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) Novartis Phase 1 Tetanus Toxoid, acellular pertussis, diphtheria toxoid Sanofi Pre-clinical ADACEL®:Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed + BOOSTRIX®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed Sanofi Approved COVAXIS™: Tetanus, diphtheria, acellular 5-component pertussis, or + inactivated poliovirus vaccine (REPEVAX®) Sanofi Approved (ADACEL®): Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis Sanofi Phase 1/2 Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and IPV + Hepatitis B vaccine Sanofi Phase 2 DTwP-HepB-Hib-IPV hexavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b, inactivated poliovirus) + DTwP-HepB-Hib pentavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b) + Inactivated Poliomyelitis Vaccine + Poliomyelitis Vaccine bivalent types 1 and 3 + Human Rotavirus, live attenuated + Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) Sanofi Phase 3 Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine Sanofi Approved Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®) + Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®) Sanofi Approved Pentacel® (DTaP-IPV/Hib) + Other Pertussis Vaccines Sanofi Pre-clinical DTaP-IPV combined vaccine + DTaP vaccine Sanofi Phase 3 ADACEL®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed + DECAVAC®: Tetanus and Diphtheria Toxoids Adsorbed Sanofi Approved Tetanus and diphtheria toxoids and acellular pertussis Sanofi Pre-clinical
Other Products from Sanofi